TARGET TO SPECIFIC LYMPHOID CELLS. PHASE I. MACROPHAGE TARGETING.

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: N/A
Agency Tracking Number: 763
Amount: $35,000.00
Phase: Phase I
Program: SBIR
Awards Year: 1983
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
939 East Walnut St., Pasadena, CA, 91106
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 JOSEPH A. ULIANA PH.D.
 PRINCIPAL INVESTIGATOR
 () -
Business Contact
Phone: () -
Research Institution
N/A
Abstract
A THREE PHASE PROJECT IS PROPOSED TO COMMERCIALIZE FORMULATIONS OF PHOSPHOLIPID VESICLES CAPABLE OF DELIVERING IMMUNOGENIC SUBSTANCES TO SPECIFIC LYMPHOID CELLS. PHASE I IS A PROOF OF CONCEPT STUDY DESIGNED TO DEMONSTRATE THAT A VESICLE FORMULATION KNOWN TO AGGRESSIVELY TARGET TO MACROPHAGE IN VITRO CAN EVOKE STRONG MACROPHAGE MEDIATED IMMUNE RESPONSES TO OTHERWISE WEAK OR NONIMMUNOGENIC HAPTEN CONJUGATES IN VIVO. PHASE I EXPERIMENTS SPECIFICALLY ADDRESS THE MACROPHAGE MEDIATED B-CELL RESPONSE AND ARE DESIGNED TO DETERMINE THE SIGNIFICANCE OF THE SIZE OF THE HAPTEN CARRIER WHEN TARGETED WITH VESICLES. PHASE I SHOULD SUGGEST ANSWERS TO THE FOLLOWING QUESTIONS: 1) IS AN ENDOCYTOSED VESICLE PROCESSED AS AN IMMUNOGEN BEFORE OR AFTER LYSIS BY MACROPHAGE? 2) ARE LYSOZOME LABILE CARRIERS PROCESSED AS ANTIGENS OR DEGRADED WHEN ENDOCYTOSED WITHIN TARGETED VESICLES? 3) ARE HAPTEN-CONJUGATES, TARGETED TO MACROPHAGE BY VESICLE ENCAPSULATION, IMMUNOGENIC AT LOWER DOSAGES THAN CONVENTIONALLY INTRODUCED HAPTEN-CONJUGATES? SUCCESSFUL COMPLETION OF PHASE I WILL DEMONSTRATE THAT IMMUNE RESPONSE CAN BE ALTERED BY PRESENTING CHEMICAL SUBSTANCES TO SPECIFIC CELLS IN A MICROENCAPSULATED FORMULATION. PHASE II WILL EXTEND THIS PRELIMINARY INVES- TIGATION OF DELIVERING HAPTEN-CONJUGATE FORMULATIONS TO MACROPHAGE TO INCORPORATE HELPER T-CELL PARTICIPATION IN THEINITIAL ANTICIPATED T-CELL INDEPENDENT RESPONSE. THE PRODUCTION OF IMMUNE RESPONSES TO WEAKLY IMMUNOGENIC OR NON-IMMUNOGENIC MATERIALS HAS SIGNIFICANT SCIENTIFIC AND MEDICALAPPLICATIONS.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government